PTCT Stock: Price, Earnings History and SEC Filings
PTC Therapeutics, Inc. (PTCT) last traded at $59.97, down 6.97% on the latest session and down 7.4% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.61 against an analyst estimate of $0.17, a beat of 258.8%.
$59.97 -6.97%
1 month-7.43%
52-week high$90.87
52-week low$58.80
Volume2.36M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PTCT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.61 | $0.17 | +258.82% |
| Jun 2026 | Jul 30, 2026 | $0.92 | $-0.17 | +641.18% |
| Mar 2026 | May 7, 2026 | $-0.03 | $-0.45 | +93.33% |
| Dec 2025 | Feb 19, 2026 | $-1.67 | $-0.21 | -695.24% |
PTCT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for PTCT
SEC filing data is not available right now. You can search for PTCT on SEC EDGAR.
PTCT news
- PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To LossOct 31, 2026 · finance.yahoo.com
- PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In FocusOct 30, 2026 · finance.yahoo.com
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 30, 2026 · finance.yahoo.com
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Which Gives You More High-Margin Software Growth, PTC Or Fair Isaac?Oct 30, 2026 · trefis.com
- PTC Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- PTC Therapeutics Q3 Earnings Call HighlightsOct 30, 2026 · marketbeat.com
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) is a US-listed public company on Nasdaq.